TableĀ 2

Research agenda

TopicsSpecific questions
Composite activity measures (mainly PsA and peripheral SpA)Validation where needed, definition of disease activity states and response categories
Remission definitionIs it important that all clinical domains of axial SpA, peripheral SpA or PsA are in remission or is it sufficient to define some of them?
Treatment targetIs there a difference in long-term outcome when comparing remission with low disease activity?
Activity and damageWhat is the progression of joint damage in different disease activity states in PsA?
Disease durationAre there differences in responsiveness and thus differences in attaining certain targets with different disease duration in PsA?
Treatment to targetThere is a need to design therapeutic trials that compare steered therapy aiming at remission or low disease activity with non-steered treatment (like TICORA)88
Axial involvement in PsADo spinal and peripheral involvements respond similarly or differently?
Enthesitis, dactylitisMore data need to be attained on the response of dactylitis or enthesitis to different therapies
Care by rheumatologistIs care of axial SpA, peripheral SpA or PsA by a rheumatologist advantageous for outcomes when compared with care by non-rheumatologists?
Maintenance of responseHow can response be maintained? Can the dose of the therapy employed be reduced or the interval of applications be expanded and outcome maintained?
PatientIs outcome different when patients are informed in a structured way when compared with more general means of information?
  • PsA, psoriatic arthritis; SpA, Spondyloarthritis.